QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 forte-biosciences-highlights-fb102s-efficacy-in-celiac-disease-at-tampere-symposium-underscoring-histological-protection-and-symptom-relief-in-phase-1b-study

Additional data continues to support highly differentiated profile for FB102 in celiac diseaseForte Biosciences, Inc. (www.fort...

 guggenheim-initiates-coverage-on-forte-biosciences-with-buy-rating-announces-price-target-of-75

Guggenheim analyst Yatin Suneja initiates coverage on Forte Biosciences (NASDAQ:FBRX) with a Buy rating and announces Price ...

 chardan-capital-maintains-buy-on-forte-biosciences-maintains-61-price-target

Chardan Capital analyst Daniil Gataulin maintains Forte Biosciences (NASDAQ:FBRX) with a Buy and maintains $61 price target.

 forte-biosciences-announces-proposed-public-offering-no-size-or-amount-disclosed

Forte Biosciences, Inc. (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related ...

 chardan-capital-maintains-buy-on-forte-biosciences-maintains-61-price-target

Chardan Capital analyst Daniil Gataulin maintains Forte Biosciences (NASDAQ:FBRX) with a Buy and maintains $61 price target.

 forte-biosciences-reports-results-in-celiac-disease-trial-paving-way-for-phase-2-in-2026

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune an...

 forte-biosciences-q1-eps-137-misses-096-estimate

Forte Biosciences (NASDAQ:FBRX) reported quarterly losses of $(1.37) per share which missed the analyst consensus estimate of $...

 forte-biosciences-files-for-mixed-shelf-of-up-to-300m

- SEC Filing

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION